BMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) saying the IP deal with Forward Pharma was ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE